In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 326 to 350 of 373

Sort by

Type: Guidance`Remove $Type: Guidance filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Technologies for the rapid diagnosis of endometriosis: early use assessment	Health technology evaluation	8 October 2026
Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628	Technology appraisal guidance	TBC
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]	Technology appraisal guidance	TBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]	Technology appraisal guidance	TBC
Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]	Technology appraisal guidance	8 October 2026
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]	Technology appraisal guidance	9 September 2026
Third molars (impacted) - prophylactic removal [ID898]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]	Technology appraisal guidance	TBC
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]	Technology appraisal guidance	10 February 2027
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]	Technology appraisal guidance	13 May 2027
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]	Highly specialised technology	17 March 2027
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis [ID6351]	Technology appraisal guidance	TBC
Tolebrutinib for treating primary progressive multiple sclerosis [ID6574]	Technology appraisal guidance	28 July 2025
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]	Technology appraisal guidance	TBC
Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713	Technology appraisal guidance	TBC
Topical tapinarof for treating mild to severe plaque psoriasis ID6712	Technology appraisal guidance	TBC
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]	Technology appraisal guidance	2 December 2026
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557]	Technology appraisal guidance	TBC
Transvaginal radiofrequency ablation for symptomatic uterine fibroids	HealthTech guidance	TBC
Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]	Technology appraisal guidance	13 January 2027
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]	Technology appraisal guidance	TBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]	Technology appraisal guidance	TBC

Results per page

10
25
50
All